The Complex Nature of Soft Tissue Sarcomas, Including Retroperitoneal Sarcomas

No abstract is available for this paper.

• Publication year

  2019

• Venue

  Current Treatment of Retroperitoneal Sarcomas

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/978-88-470-3980-3_3
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• What's in a Name? Cell Fate Reprogramming in Sarcomagenesis.

  2018cited by this paper
• Emerging Targeted and Immune-Based Therapies in Sarcoma.

  2018cited by this paper
• Advances in chromosomal translocations and fusion genes in sarcomas and potential therapeutic applications.

  2018cited by this paper
• Hedgehog Pathway Drives Fusion-Negative Rhabdomyosarcoma Initiated From Non-myogenic Endothelial Progenitors.

  2018cited by this paper
• PD-L1 and PD-1 and characterization of tumor-infiltrating lymphocytes in high grade sarcomas of soft tissue – prognostic implications and rationale for immunotherapy

  2018cited by this paper
• Modeling the Subclonal Evolution of Cancer Cell Populations.

  2018cited by this paper
• Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3.

  2018cited by this paper
• Beyond molecular tumor heterogeneity: protein synthesis takes control

  2018cited by this paper
• Current principles of surgery for retroperitoneal sarcomas

  2018cited by this paper
• Immunohistochemical analysis and prognostic significance of PD-L1, PD-1, and CD8+ tumor-infiltrating lymphocytes in Ewing’s sarcoma family of tumors (ESFT)

  2018cited by this paper
• Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials

  2017cited by this paper
• Structure of the human MHC-I peptide-loading complex

  2017cited by this paper
• Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1.

  2017cited by this paper
• Preclinical models for translational sarcoma research

  2017cited by this paper
• Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes

  2017cited by this paper
• An Emergence Framework of Carcinogenesis

  2017cited by this paper
• Prognostic value of programmed death-ligand 1 in sarcoma: a meta-analysis

  2017cited by this paper
• MAGEA4 expression in bone and soft tissue tumors: its utility as a target for immunotherapy and diagnostic marker combined with NY-ESO-1

  2017cited by this paper
• Retroperitoneal Sarcomas.

  2016cited by this paper
• Adipose-Induced Retroperitoneal Soft Tissue Sarcoma Tumorigenesis: A Potential Crosstalk between Sarcoma and Fat Cells

  2016cited by this paper
• Epigenetic and genetic changes in soft tissue sarcomas: a review

  2016cited by this paper
• Dynamics of the mammalian cell cycle in physiological and pathological conditions

  2016cited by this paper
• Molecular Changes Associated With Tumor Initiation and Progression of Soft Tissue Sarcomas: Targeting the Genome and Epigenome.

  2016cited by this paper
• Cancer: A Problem of Developmental Biology; Scientific Evidence for Reprogramming and Differentiation Therapy.

  2016cited by this paper
• Abstracts of Presentation by the winners of The Japanese Society of Pathology; Japan Pathology Award in 2016 (in program order)

  2016cited by this paper
• Cancer/Testis Antigens: Expression, Regulation, Tumor Invasion, and Use in Immunotherapy of Cancers

  2016cited by this paper
• Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment.

  2015cited by this paper
• Cancer‐testis antigens PRAME and NY‐ESO‐1 correlate with tumour grade and poor prognosis in myxoid liposarcoma

  2015cited by this paper
• Microenvironmental Targets in Sarcoma

  2015cited by this paper
• Immune escape of cancer cells with beta2‐microglobulin loss over the course of metastatic melanoma

  2014cited by this paper
• Validity and reproducibility of Ki‐67 assessment in gastrointestinal stromal tumors and leiomyosarcomas

  2013cited by this paper
• A comprehensive review of the retroperitoneal anatomy, neoplasms, and pattern of disease spread.

  2013cited by this paper
• MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells.

  2013cited by this paper
• The role of classical and non-classical HLA class I antigens in human tumors.

  2012cited by this paper
• Expression of antigen processing and presenting molecules in brain metastasis of breast cancer

  2012cited by this paper
• Targeting HLA class I expression to increase tumor immunogenicity.

  2012cited by this paper
• Lymphocyte composition and distribution in inflammatory, well-differentiated retroperitoneal liposarcoma: clues to a potential adaptive immune response and therapeutic implications.

  2012cited by this paper
• Clonal evolution in cancer

  2012cited by this paper
• Prognostic Impact of Lymphocytes in Soft Tissue Sarcomas

  2011cited by this paper
• Retroperitoneal tumours: review of management.

  2011cited by this paper
• Pro‐inflammatory chemokine–chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8+ T‐lymphocyte infiltration and affect tumour progression

  2011cited by this paper
• Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer

  2010cited by this paper
• Reduced human leukocyte antigen expression in advanced‐stage Ewing sarcoma: implications for immune recognition

  2009cited by this paper
• HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance

  2008cited by this paper
• Molecular mechanisms of MHC class I abnormalities and APM components in human tumors

  2008cited by this paper
• Immune Escape Associated with Functional Defects in Antigen-Processing Machinery in Head and Neck Cancer

  2006cited by this paper
• Molecular mechanisms of HLA class I antigen abnormalities following viral infection and transformation

  2006cited by this paper
• Association of antigen-processing machinery and HLA antigen phenotype of melanoma cells with survival in American Joint Committee on Cancer stage III and IV melanoma patients.

  2006cited by this paper
• Role of Antigen-Processing Machinery in the In Vitro Resistance of Squamous Cell Carcinoma of the Head and Neck Cells to Recognition by CTL1

  2006cited by this paper
• Colocalization of somatostatin receptors and epidermal growth factor receptors in breast cancer cells

  2006cited by this paper
• Defective Human Leukocyte Antigen Class I-associated Antigen Presentation Caused by a Novel β2-Microglobulin Loss-of-function in Melanoma Cells*

  2006cited by this paper
• Immune selective pressure and HLA class I antigen defects in malignant lesions

  2006cited by this paper
• Antigen Presentation Machinery (APM) Modulation and Soluble HLA Molecules in the Tumor Microenvironment: Do They Provide Tumor Cells with Escape Mechanisms from Recognition by Cytotoxic T Lymphocytes?

  2006cited by this paper
• HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker.

  2006cited by this paper
• Microvessel density does not predict outcome in high grade soft tissue sarcoma.

  2005cited by this paper
• Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications

  2005cited by this paper
• The complexity of anatomical systems

  2005cited by this paper
• Human Leukocyte Antigen and Antigen Processing Machinery Component Defects in Astrocytic Tumors

  2005cited by this paper
• Immunoselective pressure and human leukocyte antigen class I antigen machinery defects in microsatellite unstable colorectal cancers.

  2005cited by this paper
• Human leukocyte antigen (HLA) class I defects in head and neck cancer

  2005cited by this paper
• Defects in the Human Leukocyte Antigen Class I Antigen Processing Machinery in Head and Neck Squamous Cell Carcinoma: Association with Clinical Outcome

  2005cited by this paper
• HLA class I antigen down-regulation in primary ovary carcinoma lesions: association with disease stage.

  2005cited by this paper
• Identification of cancer-testis genes expressed by melanoma and soft tissue sarcoma using bioinformatics.

  2005cited by this paper
• Soft-tissue sarcomas in adults.

  2005cited by this paper
• Down-regulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma?

  2004cited by this paper
• HLA Antigen Changes in Malignant Tumors of Mammary Epithelial Origin: Molecular Mechanisms and Clinical Implications

  2004cited by this paper
• Journal of Translational Medicine BioMed Central Commentary Cancer immunotherapy: avoiding the road to perdition

  2004cited by this paper
• Classification and subtype prediction of adult soft tissue sarcoma by functional genomics.

  2003cited by this paper
• Association of tapasin and HLA class I antigen down-regulation in primary maxillary sinus squamous cell carcinoma lesions with reduced survival of patients.

  2003cited by this paper
• HLA class I defects in malignant lesions: what have we learned?

  2003cited by this paper
• MHC class I‐deficient metastatic tumor variants immunoselected by T lymphocytes originate from the coordinated downregulation of APM components

  2003cited by this paper
• HLA class I antigen abnormalities and immune escape by malignant cells.

  2002cited by this paper
• Cancer immunoediting: from immunosurveillance to tumor escape

  2002cited by this paper
• HLA class I antigen loss, tumor immune escape and immune selection.

  2002cited by this paper
• Quantitative and Qualitative Influences of Tapasin on the Class I Peptide Repertoire1

  2001cited by this paper
• Tapasin-Mediated Retention and Optimization of Peptide Ligands During the Assembly of Class I Molecules1

  2000cited by this paper
• Impaired assembly yet normal trafficking of MHC class I molecules in Tapasin mutant mice.

  2000cited by this paper
• Impaired immune responses and altered peptide repertoire in tapasin-deficient mice

  2000cited by this paper
• Cytogenetics and the biologic basis of sarcomas

  2000cited by this paper
• Different patterns of angiogenesis in sarcomas and carcinomas.

  1999cited by this paper
• Cytogenetics and the biological basis of sarcomas.

  1998cited by this paper
• Mechanisms of MHC class I--restricted antigen processing.

  1998cited by this paper
• Soluble tapasin restores MHC class I expression and function in the tapasin-negative cell line .220.

  1998cited by this paper
• HLA-B27-restricted antigen presentation in the absence of tapasin reveals polymorphism in mechanisms of HLA class I peptide loading.

  1998cited by this paper
• A critical role for tapasin in the assembly and function of multimeric MHC class I-TAP complexes.

  1997cited by this paper
• Molecular genetics and cytogenetics of sarcomas.

  1995cited by this paper
• Altered patterns of retinoblastoma gene product expression in adult soft-tissue sarcomas.

  1995cited by this paper
• Generation, translocation, and presentation of MHC class I-restricted peptides.

  1995cited by this paper
• The Li-Fraumeni syndrome: from clinical epidemiology to molecular genetics.

  1992cited by this paper
• Mutation of the p53 gene in human soft tissue sarcomas: association with abnormalities of the RB1 gene.

  1990cited by this paper
• Theoretical Biology and Medical Modelling Open Access Cancer Initiation and Progression: an Unsimplifiable Complexity

  year unknowncited by this paper

• No citing papers are available for this paper.